Wednesday, April 26, 2017

Jurisdiction 9 Review to Finalization Timelines for LCDs

LCD Title Comment Open Comment End Status*   Days in review
DL34217 Intensity Modulated Radiation Therapy (IMRT) 2/4/2016 4/10/2016 NRTF N/A  
381
DL36696 Hyperbaric Oxygen (HBO) Therapy 6/2/2016 8/8/2016 NRTF N/A   261
DL36698 Intraoperative Neurophysiological Testing 6/2/2016 8/8/2016 NRTF N/A  
261
DL34213 Diagnostic and Therapeutic Colonoscopy 10/6/2016 12/15/2016 NRTF N/A   132
DL34317 Chest X-Ray Policy 10/6/2016 12/15/2016 NRTF N/A   132
DL34324 Cardiovascular Stress Testing, Including Exercise and/or Pharmacological Stress and Stress Echocardiography 10/6/2016 12/15/2016 NRTF N/A   132
DL36864 GlycoMark Testing for Glycemic Control 10/6/2016 12/15/2016 NRTF N/A  
132
DL36846 Measurement of Salivary Hormones 10/6/2016 12/15/2016 NRTF N/A   132
DL34203 Cataract Surgery in Adults 2/8/2017 4/10/2017 NRTF N/A   16
DL37120 4Kscore Assay 2/8/2017 4/10/2017 NRTF N/A   16
DL37066 Coenzyme Q10 (CoQ10) 2/8/2017 4/10/2017 NRTF N/A   16
DL37060 MolDX: Vita Risk™ Pharmacogenetic Test for Dry Age-related Macular Degeneration (AMD) 2/8/2017 4/10/2017 NRTF N/A   16
DL37090 MolDX: VectraDA, a Multibiomarker Disease Activity Test for Rheumatoid Arthritis (RA) 2/8/2017 4/10/2017 NRTF N/A  
16
DL37054 MolDX: Xpresys Lung 2/8/2017 4/10/2017 NRTF N/A  
16
DL37086 Repetitive Transcranial Magnetic Stimulation (rTMS) in Adults with Treatment Resistant Major Depressive Disorder 2/8/2017 4/10/2017 NRTF N/A   16
DL35163 Plastic Surgery 2/8/2017 4/10/2017 NRTF N/A  
16
DL37080 MolDX: Prolaris™ Prostate Cancer Genomic Assay for Men with Favorable Intermediate Risk Disease 2/8/2017 4/10/2017 NRTF N/A   16
DL37101 MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Advanced Primary Peritoneal, Fallopian Tube and Ovarian Cancer 2/8/2017 4/10/2017 NRTF N/A  
16
DL37114 Visual Electrophysiology Testing 2/8/2017 4/10/2017 NRTF N/A  
16
DL37105 MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Colorectal Cancer 2/8/2017 4/10/2017 NRTF N/A   16
DL37070 MolDX: DecisionDx-UM (Uveal Melanoma) 2/8/2017 4/10/2017 NRTF N/A  
16
DL37109 MolDX: Comprehensive Genomic Profiling to Guide Treatment in Patients with Metastatic Melanoma 2/8/2017 4/10/2017 NRTF N/A   16
DL36704 MolDX- CDD: ProMark Risk Score 6/2/2016 8/8/2016 RTF N/A  
221
DL36886 MolDX-CDD: Percepta© Bronchial Genomic Classifier 10/6/2016 12/15/2016 RTF N/A   92
DL34218 Injections - Tendon, Ligament, Ganglion Cyst, Tunnel Syndromes and Morton's Neuroma 10/6/2016 12/15/2016 RTF N/A   92
DL34211 Trigger Point Injections 10/6/2016 12/15/2016 RTF N/A   92
DL36882 MolDX: APC and MUTYH Gene Testing 10/6/2016 12/15/2016 RTF N/A   92
DL36941 MolDX - CDD: Oncotype DX® Breast Cancer for DCIS (Genomic Health ™) 10/6/2016 12/30/2016 RTF L   77


*NRTF _ Not released to final.   RTF_ Released to final
Posted by at

1 comment:

  1. Jhon macOctober 13, 2018 at 4:30 AM

    Thanks for shearing about Pharmacogenetic test. I thinks its very helpful post and very important post for us. Really this post will be helpful for all king of people to awareness. So i appreciate your post.
    Pharmacogenetic test

    ReplyDelete

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)